CADL (Candel) Earnings per share growth rate in current year
Candel Therapeutics (CADL) is integrating ESG principles into the development of anticancer immunotherapies by reducing laboratory waste. On GURU.Markets, the annual earnings per share trend shows that the current metric is -80.00. The robotization of drug synthesis is accelerating development, although physicians remain indispensable. Meanwhile, the company's eco-policy remains formal, limited to digital documentation and the monitoring of chemical disposal.
Financial and market metric breakdowns for Candel Therapeutics (CADL)
- stock price and consensus target price:
- business market valuation indicators:
- balance sheet equity data:
- debt burden and liquidity indicators:
Debt to Equity Ratio Candel Therapeutics|CADL - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio Candel Therapeutics Inc.|CADL - Company Aggregate Debts|Debts to Book Value Candel Therapeutics, Inc.|CADL - Company Long-Term Debt|Company Short-Term Debt Candel Therapeutics|Intermediate Coverage Ratio candeltx.com
- net income and valuation ratios data:
CADL - Net Income|Future Net Profit Candel Therapeutics|CADL - P/E Multiple|Future Price to Earnings Multiple Candel Therapeutics Inc.|CADL - PEG Multiple|Company Value to EBITDA Candel Therapeutics, Inc.|CADL - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Candel Therapeutics|CADL - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth candeltx.com|CADL - Earnings per share growth in current year|Net earnings per share change forecast for next year Candel Therapeutics
- sales volume and revenue information:
Fundamental valuation:CADL candeltx.com
The eps_yy_co metric measures the annual percentage change in earnings per share, reflecting the efficiency of profit generation or the rate of loss reduction relative to the previous year. By analyzing the relative EPS YoY dynamics, an investor can see the impact of cost management for clinical trials and grants at Candel Therapeutics (CADL), which is critical for assessing the company's financial stability prior to the commercialization stage.
Main competitors
Earnings per share growth rate in current year BeiGene Corp (ONC)|HALO (Halozyme Therapeutics, Inc.) - Earnings growth in current year|Earnings per share growth rate in current year revmed.com RVMD|Earnings growth in current year AAPG|Net earnings per share growth this year CG Oncology CGON|Earnings per share growth in current year UroGen URGN|Expected net earnings per share growth this year Bicara Bio (BCAX)|PSNL - Earnings per share growth in current year|ERAS - Earnings growth in current year|DCTH: Earnings growth in current year|Y-mAbs Therapeutics, Inc. (YMAB) - Earnings growth in current year|Net earnings per share growth this year AURA|ARAY: Earnings per share increase in current year|Net earnings per share growth this year SLS (SELLAS Life Sciences Group, Inc.)|Net earnings per one share growth for the current year ACTU|Citius Oncology - Net earnings per share growth this year|Earnings per share increase in current year HURA|TARA: Net earnings per share growth this year|Earnings per share growth rate in current year Fate Pharma|Aadi Bioscience Inc (WHWK) - Earnings per share growth in current year|Earnings per share growth rate in current year TScan (TCRX)|Net earnings per share growth this year CSBR|xbiotech.com (XBIT) - Expected net earnings per share growth this year|Earnings per share growth in current year cel-sci.com (CVM)|OSTX - Earnings per share growth rate in current year|Radiopharm Theranostics - Net earnings per share growth this year|Earnings per share increase in current year ARTV|ANL - Earnings per share growth in current year|VERU - Earnings growth in current year|Tempest Therapeutics, Inc. (TPST) - Earnings per share growth in current year|XLO: Net earnings per one share growth for the current year|RENB (Renovaro Biosciences) - Earnings growth in current year|MURA: Earnings per share increase in current year|Net earnings per share growth this year KAPA (Kairos Pharma Ltd)|Net earnings per one share growth for the current year OKUR|CytoMed Therapeutics Limited - Net earnings per share growth this year|CRIS: Earnings per share growth this year|APLM - Earnings per share growth in current year|THAR - Earnings growth in current year|ADVB: Earnings growth in current year|Earnings per share growth this year GNPX|CLDI (Calidi Biotherapeutics, Inc.) - Earnings growth in current year|Earnings per share growth in current year SBFM|Earnings growth in current year XBIO|Net earnings per share growth this year Salarius Pharmaceuticals SLRX|Earnings growth in current year PPBT (Purple Biotech Ltd)|AONC - Net earnings per share growth this year|BGNE: Net earnings per share growth this year|Expected net earnings per share growth this year Checkpoint Therapeutics, Inc CKPT|ELEV: Earnings growth in current year|Earnings per share growth rate in current year iCAD Inc. (ICAD)|IKNA (Ikena) - Earnings growth in current year|Net earnings per share growth this year Notable Labs (NTBL)|Earnings growth in current year VIRX|Net earnings per share growth this year MorphoSys Corporation MOR|NAYA Biosciences - Net earnings per share growth this year|Net earnings per share change in current year Ascentage Pharma
